Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of dermatitis comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dermatitis for each country,…

DRG Epidemiology’s coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of cervical…

DRG Epidemiology’s coverage of osteoarthritis (OA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of OA in each country, as…

We review the published literature, including online registries and surveys, using a systematic search with a defined date range, for the most representative epidemiological data on MCI.We…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

DRG Epidemiology’s coverage of myelodysplastic syndromes comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of hospital treated (HT) gram-negative infections (GNIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

DRG Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PAD for each…

DRG Epidemiology’s coverage of minor depression comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of minor depression for each…

DRG Epidemiology’s coverage of major depressive disorder (MDD) (DSM-IV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of MDD…

DRG Epidemiology’s coverage of dysthymia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dysthymia for each country, as…

MARKET OUTLOOK Progress in R&D and technology, regulatory and monetary incentives for advancing the development of rare diseases treatment, and ongoing industry focus are key drivers of growth in…